Xenon announces new data on 48-month azetukalner OLE study data

Xenon Pharmaceuticals (XENE) announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension, OLE, study of azetukalner in patients with focal onset seizures, multiple real world studies on the burden of depression and anti-seizure medication titration in epilepsy, and new data for its pre-clinical program in Dravet syndrome. These data are being presented at the American Epilepsy Society Annual Meeting, taking place December 5-9, 2025 in Atlanta, Georgia. Monthly reductions in seizure frequency of 90.9% among participants treated for greater than or equal to48 months in the OLE, with 38% achieving greater than or equal to 1 year of seizure freedom; New X-TOLE OLE data analysis supports the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner, even in patients with difficult-to-treat disease; Four real-world study posters illustrate significant burden of depression and ASM titration on people living with epilepsy; poster on impact of depression on outcomes and treatment patterns in patients with newly diagnosed epilepsy highlighted in AES press program; New pre-clinical data in Dravet syndrome suggest potential to improve motor function through NaV1.1 potentiation